FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093694511> ?p ?o ?g. }

• W2093694511 endingPage "e49279" @default.
• W2093694511 startingPage "e49279" @default.
• W2093694511 abstract "Aim To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients. To analyze the impact of metformin on glutaminase activity and ammonia production in vitro. Methods Eighty-two cirrhotic patients with type 2 diabetes were included. Forty-one patients were classified as insulin sensitizers experienced (metformin) and 41 as controls (cirrhotic patients with type 2 diabetes mellitus without metformin treatment). Baseline analysis included: insulin, glucose, glucagon, leptin, adiponectin, TNFr2, AST, ALT. HOMA-IR was calculated. Baseline HE risk was calculated according to minimal hepatic encephalopathy, oral glutamine challenge and mutations in glutaminase gene. We performed an experimental study in vitro including an enzymatic activity assay where glutaminase inhibition was measured according to different metformin concentrations. In Caco2 cells, glutaminase activity inhibition was evaluated by ammonia production at 24, 48 and 72 hours after metformina treatment. Results Hepatic encephalopathy was diagnosed during follow-up in 23.2% (19/82): 4.9% (2/41) in patients receiving metformin and 41.5% (17/41) in patients without metformin treatment (logRank 9.81; p = 0.002). In multivariate analysis, metformin use [H.R.11.4 (95% CI: 1.2–108.8); p = 0.034], age at diagnosis [H.R.1.12 (95% CI: 1.04–1.2); p = 0.002], female sex [H.R.10.4 (95% CI: 1.5–71.6); p = 0.017] and HE risk [H.R.21.3 (95% CI: 2.8–163.4); p = 0.003] were found independently associated with hepatic encephalopathy. In the enzymatic assay, glutaminase activity inhibition reached 68% with metformin 100 mM. In Caco2 cells, metformin (20 mM) decreased glutaminase activity up to 24% at 72 hours post-treatment (p<0.05). Conclusions Metformin was found independently related to overt hepatic encephalopathy in patients with type 2 diabetes mellitus and high risk of hepatic encephalopathy. Metformin inhibits glutaminase activity in vitro. Therefore, metformin use seems to be protective against hepatic encephalopathy in diabetic cirrhotic patients." @default.
• W2093694511 created "2016-06-24" @default.
• W2093694511 creator A5022028309 @default.
• W2093694511 creator A5031957769 @default.
• W2093694511 creator A5037480677 @default.
• W2093694511 creator A5040707395 @default.
• W2093694511 creator A5044156779 @default.
• W2093694511 creator A5047229260 @default.
• W2093694511 creator A5050030745 @default.
• W2093694511 creator A5051066150 @default.
• W2093694511 creator A5083797541 @default.
• W2093694511 creator A5085550667 @default.
• W2093694511 creator A5085764522 @default.
• W2093694511 date "2012-11-15" @default.
• W2093694511 modified "2023-10-16" @default.
• W2093694511 title "Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy" @default.
• W2093694511 cites W1534128191 @default.
• W2093694511 cites W1957302801 @default.
• W2093694511 cites W1964873462 @default.
• W2093694511 cites W1969648331 @default.
• W2093694511 cites W1971689007 @default.
• W2093694511 cites W1985424490 @default.
• W2093694511 cites W2002376489 @default.
• W2093694511 cites W2009888627 @default.
• W2093694511 cites W2012022623 @default.
• W2093694511 cites W2013213790 @default.
• W2093694511 cites W2021886567 @default.
• W2093694511 cites W2033976318 @default.
• W2093694511 cites W2041998249 @default.
• W2093694511 cites W2052882363 @default.
• W2093694511 cites W2079454650 @default.
• W2093694511 cites W2092488871 @default.
• W2093694511 cites W2125841917 @default.
• W2093694511 cites W4205321574 @default.
• W2093694511 doi "https://doi.org/10.1371/journal.pone.0049279" @default.
• W2093694511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3499552" @default.
• W2093694511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23166628" @default.
• W2093694511 hasPublicationYear "2012" @default.
• W2093694511 type Work @default.
• W2093694511 sameAs 2093694511 @default.
• W2093694511 citedByCount "49" @default.
• W2093694511 countsByYear W20936945112013 @default.
• W2093694511 countsByYear W20936945112014 @default.
• W2093694511 countsByYear W20936945112015 @default.
• W2093694511 countsByYear W20936945112016 @default.
• W2093694511 countsByYear W20936945112017 @default.
• W2093694511 countsByYear W20936945112018 @default.
• W2093694511 countsByYear W20936945112019 @default.
• W2093694511 countsByYear W20936945112020 @default.
• W2093694511 countsByYear W20936945112021 @default.
• W2093694511 countsByYear W20936945112022 @default.
• W2093694511 countsByYear W20936945112023 @default.
• W2093694511 crossrefType "journal-article" @default.
• W2093694511 hasAuthorship W2093694511A5022028309 @default.
• W2093694511 hasAuthorship W2093694511A5031957769 @default.
• W2093694511 hasAuthorship W2093694511A5037480677 @default.
• W2093694511 hasAuthorship W2093694511A5040707395 @default.
• W2093694511 hasAuthorship W2093694511A5044156779 @default.
• W2093694511 hasAuthorship W2093694511A5047229260 @default.
• W2093694511 hasAuthorship W2093694511A5050030745 @default.
• W2093694511 hasAuthorship W2093694511A5051066150 @default.
• W2093694511 hasAuthorship W2093694511A5083797541 @default.
• W2093694511 hasAuthorship W2093694511A5085550667 @default.
• W2093694511 hasAuthorship W2093694511A5085764522 @default.
• W2093694511 hasBestOaLocation W20936945111 @default.
• W2093694511 hasConcept C126322002 @default.
• W2093694511 hasConcept C134018914 @default.
• W2093694511 hasConcept C185592680 @default.
• W2093694511 hasConcept C2777180221 @default.
• W2093694511 hasConcept C2777214474 @default.
• W2093694511 hasConcept C2777391703 @default.
• W2093694511 hasConcept C2779306644 @default.
• W2093694511 hasConcept C2779349466 @default.
• W2093694511 hasConcept C2780323712 @default.
• W2093694511 hasConcept C2780325230 @default.
• W2093694511 hasConcept C515207424 @default.
• W2093694511 hasConcept C55493867 @default.
• W2093694511 hasConcept C555293320 @default.
• W2093694511 hasConcept C71924100 @default.
• W2093694511 hasConcept C90924648 @default.
• W2093694511 hasConceptScore W2093694511C126322002 @default.
• W2093694511 hasConceptScore W2093694511C134018914 @default.
• W2093694511 hasConceptScore W2093694511C185592680 @default.
• W2093694511 hasConceptScore W2093694511C2777180221 @default.
• W2093694511 hasConceptScore W2093694511C2777214474 @default.
• W2093694511 hasConceptScore W2093694511C2777391703 @default.
• W2093694511 hasConceptScore W2093694511C2779306644 @default.
• W2093694511 hasConceptScore W2093694511C2779349466 @default.
• W2093694511 hasConceptScore W2093694511C2780323712 @default.
• W2093694511 hasConceptScore W2093694511C2780325230 @default.
• W2093694511 hasConceptScore W2093694511C515207424 @default.
• W2093694511 hasConceptScore W2093694511C55493867 @default.
• W2093694511 hasConceptScore W2093694511C555293320 @default.
• W2093694511 hasConceptScore W2093694511C71924100 @default.
• W2093694511 hasConceptScore W2093694511C90924648 @default.
• W2093694511 hasIssue "11" @default.
• W2093694511 hasLocation W20936945111 @default.
• W2093694511 hasLocation W20936945112 @default.

• next